Enroll Now

Active Studies Enrolling now

Jadestone is contracted by White Oak Medical Center to support and manage research consistent with the mission and values of  the organization.

NIH Recover Sleep flyer

NIH Recover Sleep

Who qualifies?

  • Adults who had COVID
  • 1 or more of these symptoms:
    • Problems falling asleep or staying asleep
    • Poor sleep quality
    • Trouble staying awake or feeling very tired during the day
    • Insomnia or problems with your sleep-wake schedule.

Intervention: 

  • Study lasts about 3 to 4 months. 
  • Use study medication and wear study device at no cost.
  • Visit the clinic 2 to 3 times to complete surveys and tests. 

Stipend: up to $1,350.

Enroll Now
NIH long Covid RECOVER VITAL

NIH Recover Vital

Who qualifies?

Adults who have one or more of the following symptoms associated with COVID for at least 12 weeks:

low energy, trouble focusing or brain fog, dizziness, fast heart rate, shortness of breath, upset stomach, arm and leg pain or weakness, or other symptoms.

Intervention: 

  • Study lasts for 6 months.
  • Take a study drug, at no cost.
  • 4 to 5 clinic visits to complete surveys and tests.  
  • Answer follow-up surveys online or by phone.


Stipend: up to $2,650.

Enroll Now
NIH Long COVID Recover Neuro

NIH Recover Neuro

Who qualifies?

  • Adult who had COVID.
  • You still have 1 or more of these symptoms: 
  • Brain fog, trouble thinking clearly, trouble paying attention, remembering things.

Intervention: 

  • Study lasts about 6 months. 
  • Visit the clinic 3 times to complete surveys, lab tests, and brain function tests 
  • Complete brain training sessions at home for 10 weeks


Stipend: to $3,950.

Enroll Now

NIH Recover Energize

Criteria

18 years old and above who developed exercise intolerance after COVID19 infection.

Intervention: 

rehabilitation to improve exercise capacity, daily activities tolerance, and quality of life


Stipend: up to $1,900.

Enroll Now
GSK-RSV

GSK Phase 3b RSV Vaccine Study

Who qualifies?

  • 18 – 49 years old with at least 1 of the following medical conditions COPD, Asthma, Cystic Fibrosis. CHF, Pre-existing CAD, Cardiac arrhythmia, Diabetes type 1 or 2 , chronic kidney disease, Chronic moderate to severe liver disease, neurologic or neuromuscular conditions 
  • Or 60 years old and above who are Immunosuppressed or immunocompromised.  

Intervention: 

  • One study vaccine/shot. 
  • Study lasts 6 months. 
  • 3 visits consisting of Day 1, 31-day,  and 6-month

 

Stipend: up to $470.

Enroll Now
NIH Fluvid Vaccine Research

Pfizer Phase 3 Fluvid (flu+covid) Vaccine Study

Who qualifies?

  • 18 – 64 years old.
  • Have not received the flu or covid vaccine within 6 months prior to enrollment.

Intervention: 

  • 4 visits consisting of Day 1 with Fluvid shot, 4-week and 6-month followup visits. 
  • Study lasts 6 months.

 

Stipend: $650.

Enroll Now

Examples of Closed Studies

Learn about past studies

A large clinical research study testing existing medications for use on adults with mild-to-moderate COVID-19 symptoms who are not sick enough to be hospitalized.

Medication: Metformin

Eligibility:

  • 30 years old or older
  • Have tested positive for COVID-19 within the last 10 days
  • Since testing positive, have had two or more COVID-19 symptoms

Stipend: $125

Duration: 1 month + 90 days (all remote)

For more information on this study

Sponsor:  Invivyd, Inc.

 A study to investigate the prevention of COVID-19 with VYD222 in adults with immune compromise and in participants aged 12 years or older who are at risk of exposure to SARS-CoV-2

Eligibility:

  • 12 years old or above

  • At risk of exposure to COVID or immune compromised.

  • No current covid symptoms or infection

  • Not exposed to covid in 5 days

Study treatment: VYD222 (investigational monoclonal antibody)

Duration: 12 months. 

Stipend: up to $900

For more information on this study

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease (MONET)

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease (MONET)

Criteria: 

  • 18 years old and above
  • Considered having a high likelihood of severe RSV disease due to certain long-term
  • medical conditions Or considered having a weakened immune system.

Study duration: 6 months

Stipend: up to $395 (2 visits and 1 phone call)

For more information on this study

A phase 3, double-blind, placebo-controlled study to determine the efficacy and safety/tolerability of molnupiravir (MK-4482) in adults for the prevention of COVID-19.

For more information

This NIH research was to determine if taking a commonly prescribed blood thinner either Apixiban (commonly known as Eliquis) or Aspirin is better than taking no blood thinner for people who test positive for COVID-19.

For more information

This phase 2/3 study tested how safe and effective the Merck oral Molnupiravir antiviral study drug is that may help reduce COVID-19 symptoms, recovery time, and prevent hospitalizations for people with COVID-19.

For more information on this study

A phase I trial analyzing the safety, tolerability, pharmacokinetics and serum SARS-CoV-2 neutralizing antibody levels of different doses of the antibody treatment.

For more information

This study looked to see if Asapiprant is well tolerated and can help older patients with weaker immune systems fight off the COVID-19 virus.

For more information

A randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of a treatment drug in patients with uncontrolled hypertension and chronic kidney disease (CKD).

For more information

Jadestone logo on white

Contact

240-904-4568 | [email protected]
11886 Healing Way, Suite 204 Silver Spring, MD 20904

Copyright © 2024 Jadestone Clinical Research LLC